Dr. Pilar Eroles Asensio

Principal Investigator
Research Group on Breast Cancer Biology

Presentation

Dr. Eroles, a Miguel Servet researcher at the Carlos III National Health Institute, joined the Hospital Clínico de Valencia Research Foundation, currently the INCLIVA Research Institute, in 2004. In 2009, she was consolidated as a researcher within INCLIVA and she is currently Co-Principal Investigator of the Breast Cancer Biology Group of the institution.

Her line of research focuses on the study of the mechanisms of resistance to current treatments in breast cancer, evaluating the participation of the epithelial-mesenchymal transition, epigenetic modifications and the regulation of the tumor microenvironment. The objective of the group is to develop new therapeutic strategies to reverse resistance, based on the combination of biological agents and the development of new treatments such as nanoparticles.

She has participated in more than 30 funded projects, in 8 of them as principal investigator. She has publications in journals such as Cancer Cell, Blood, European Journal of Cancer and Oncotarget among others. She is an Associate Professor in the Department of Physiology of the Faculty of Medicine of the University of Valencia.

She has directed 8 completed doctoral theses and 3 currently in progress, as well as master’s degree projects and end-of-degree projects. She is a member of the INCLIVA Research Commission, a reviewer in several international scientific journals and an evaluator for the National Agency for Quality Assessment and Accreditation-ANECA.

Principal
Investigator
Dr. Pilar Eroles Asensio

pilar.eroles@uv.es

Publications
Delivery of miR-200c-3p using tumor-targeted mesoporous silica nanoparticles for breast cancer therapy. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. ACS Applied Materials & Interfaces. 2023 Aug 16;15(32):38323-38334. doi: 10.1021/acsami.3c07541. PMID: 37549382

High VEGFR3 expression reduces doxorubicin efficacy in triple-negative breast cancer. Torres Ruiz S, Tormo E, Garrido Cano I, Lameirinhas A, Rojo F, Madoz Gurpide J, Burgues O, Hernando C, Bermejo B, Martinez MT, Lluch A, Cejalvo JM, Eroles P. International Journal of Molecular Sciences. 2023 Feb 10;24(4):3601. doi: 10.3390/ijms24043601. PMID: 36835014

miR-146a-5p promotes angiogenesis and confers trastuzumab resistance in HER2+ breast cancer. Cabello P, Torres-Ruiz S, Adam-Artigues A, Fores-Martos J, Martinez M, Hernando C, Zazo S, Madoz-Gurpide J, Rovira A, Burgues O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo J, Eroles P. Cancers. 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138. PMID: 37046799

Antagonists of the Mu-opioid receptor in the cancer patient: fact or fiction?. Belltall A, Mazzinari G, Diaz-Cambronero O, Eroles P, Navarro M. Current Oncology Reports. 2022 Oct;24(10):1337-1349. doi: 10.1007/s11912-022-01295-z. PMID: 35648340

CIP2A as a key regulator for AKT phosphorylation has partial impact determining clinical outcome in breast cancer. Luque M, Cristobal I, Sanz-Alvarez M, Santos A, Zazo S, Eroles P, Arpi O, Rovira A, Albanell J, Madoz-Gurpide J, Garcia-Foncillas J, Rojo F. Journal of Clinical Medicine. 2022 Mar 14;11(6):1610. doi: 10.3390/jcm11061610. PMID: 35329936

MicroRNAs as a clue to overcome breast cancer treatment resistance. Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. Cancer Metastasis Reviews. 2022 Mar;41(1):77-105. doi: 10.1007/s10555-021-09992-0. PMID: 34524579

miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Rojo F, Zazo S, Madoz-Gurpide J, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. Cancer Communications. 2022 Dec;42(12):1412-1416. doi: 10.1002/cac2.12352. PMID: 35997029

mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer. Casadevall D, Hernandez-Prat A, Garc A-Alonso S, Arpi-Llucia O, Menendez S, Qin M, Guardia C, Morancho B, Sanchez-Mart N F, Zazo S, Gavilan E, Sabbaghi M, Eroles P, Cejalvo J, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Molecular Cancer Research. 2022 Jul 6;20(7):1108-1121. doi: 10.1158/1541-7786.MCR-21-0545. PMID: 35348729

Opioid receptor expression in colorectal cancer: a nested matched case-control study. Belltall A, Mazzinari G, Garrido-Cano I, Giner F, Mari A, Eroles P, Argente-Navarro M, Cata J, Diaz-Cambronero O. Frontiers in Oncology. 2022 Apr 6;12:801714. doi: 10.3389/fonc.2022.801714. PMID: 35463331

Role of SALL4 in HER2+breast cancer progression: regulating PI3K/AKT Pathway. Pattanayak B, Lameirinhas A, Torres-Ruiz S, Burgues O, Rovira A, Martinez M, Tapia M, Zazo S, Albanell J, Rojo F, Bermejo B, Eroles P. International Journal of Molecular Sciences. 2022 Oct 31;23(21):13292. doi: 10.3390/ijms232113292. PMID: 36362083

Solid tumor opioid receptor expression and oncologic outcomes: analysis of the cancer genome atlas and genotype tissue expression Project. Belltall A, Zuniga-Trejos S, Garrido-Cano I, Eroles P, Argente-Navarro M, Buggy D, Diaz-Cambronero O, Mazzinari G. Frontiers in Oncology. 2022 Mar 10;12:801411. doi: 10.3389/fonc.2022.801411. PMID: 35359418

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Adam-Artigues A, Arenas E, Martinez-Sabadell A, Braso-Maristany F, Cervera R, Tormo E, Hernando C, Martinez M, Carbonell-Asins J, Simon S, Poveda J, Moragon S, Zazo S, Martinez D, Rovira A, Burgues O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo J. Science Advances. 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. PMID: 35594351

Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel. Jimenez N, Reig O, Marin-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, Rodriguez-Vida A, Climent MA, Cros S, Chirivella I, Domenech M, Figols M, Gonzalez-Billalabeitia E, Jimenez Peralta D, Rodriguez-Carunchio L, Garcia-Esteve S, Garcia de Herreros M, Ribal MJ, Prat A, Mellado B. Cancers. 2022 Sep 29;14(19):4757. doi: 10.3390/cancers14194757. PMID: 36230681

Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression. Fores-Martos J, Cervera-Vidal R, Sierra-Roca J, Lozano-Asencio C, Fedele V, Cornelissen S, Edvarsen H, Tadeo-Cervera I, Eroles P, Lluch A, Tabares-Seisdedos R, Falco A, Van’t Veer LJ, Schmidt M, Quigley DA, Borresen-Dale AL, Kristensen VN, Balmain A, Climent J. NPJ Breast Cancer. 2021 Sep 10;7(1):118. doi: 10.1038/s41523-021-00329-2. PMID: 34508103

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer. Adam-Artigues A, Garrido-Cano I, Simon S, Ortega B, Moragon S, Lameirinhas A, Constancio V, Salta S, Burgues O, Bermejo B, Henrique R, Lluch A, Jeronimo C, Eroles P, Cejalvo J. ESMO Open. 2021 Jan 18;6(1):100039. doi: 10.1016/j.esmoop.2020.100039. PMID: 33477007

Expression of phosphorylated BRD4 is markedly associated with the activation status of the PP2A pathway and shows a strong prognostic value in triple negative breast cancer patients. Sanz-Alvarez M, Cristobal I, Luque M, Santos A, Zazo S, Madoz-Gurpide J, Carames C, Chiang C, Garcia-Foncillas J, Eroles P, Albanell J, Rojo F. Cancers. 2021 Mar 12;13(6):1246. doi: 10.3390/cancers13061246. PMID: 33809005

Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool. Garrido-Cano I, Pla L, Santiago-Felipe S, Simon S, Ortega B, Bermejo B, Lluch A, Cejalvo J, Eroles P, Martinez-Manez R. ACS Sensors. 2021 Mar 26;6(3):1022-1029. doi: 10.1021/acssensors.0c02222. PMID: 33599490

Oral Selective Estrogen Receptor Degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Hernando C, Ortega-Morillo B, Tapia M, Moragon S, Martinez M, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B, Cejalvo J. International Journal of Molecular Sciences. 2021 Jul 22;22(15):7812. doi: 10.3390/ijms22157812. PMID: 34360578

Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer. Guardia C, Bianchini G, Arpi-LLucia O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero J, Soria-Jimenez L, Sabbaghi M, Pena R, Madoz-Gurpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Clinical Cancer Research. 2021 Sep 15;27(18):5096-5108. doi: 10.1158/1078-0432.CCR-20-2915. PMID:34385295

Targeted therapy modulates the secretome of cancer-associated fibroblasts to induce resistance in HER2-positive breast cancer. Luque M, Sanz-Alvarez M, Santamaria A, Zazo S, Cristobal I, de la Fuente L, Minguez P, Eroles P, Rovira A, Albanell J, Madoz-Gurpide J, Rojo F. International Journal of Molecular Sciences. 2021 Dec 10;22(24):13297. doi: 10.3390/ijms222413297. PMID: 34948097

Autocrine CCL5 effect mediates trastuzumab resistance by ERK pathway activation in HER2-positive breast cancer. Zazo S, Gonzalez-Alonso P, Martin-Aparicio E, Chamizo C, Luque M, Sanz-Alvarez M, Minguez P, Gomez-Lopez G, Cristobal I, Carames C, Garcia-Foncillas J, Eroles Asensio P, Lluch Hernández A, Arpi O, Rovira A, Albanell J, Madoz-Gurpide J, Rojo F. Molecular Cancer Therapeutics. 2020 Aug;19(8):1696-1707. doi: 10.1158/1535-7163.MCT-19-1172. PMID: 32404410

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer. Garrido Cano I, Constancio V, Adam Artigues A, Lameirinhas A, Simon Alonso S, Ortega Morillo B, Martinez Martinez M, Hernando Meliá C, Bermejo De Las Heras B, Lluch Hernández A, Lopes P, Henrique R, Jeronimo C, Cejalvo Andujar J, Eroles Asensio P. International Journal of Molecular Sciences. 2020 Oct 8;21(19):7427. doi: 10.3390/ijms21197427. PMID: 33050096

Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia. Ballester Garcia S, Pineda Merlo B, Rodrigues P, Tormo Martin E, Terol Castera M, Eroles Asensio P. Genes. 2020 Jun 23;11(6):686. doi: 10.3390/genes11060686. PMID: 32585853

Combination of phenotype and polygenic risk score in breast cancer risk evaluation in the Spanish population: a case -control study. Trivino J, Ceba A, Rubio-Solsona E, Serra D, Sanchez-Guiu I, Ribas G, Rosa R, Cabo M, Bernad L, Pita G, Gonzalez-Neira A, Legarda G, Diaz J, García Vigara A, Martinez Aspas A, Escrig M, Bermejo De Las Heras B, Eroles Asensio P, Ibanez J, Salas D, Julve Parreño A, Cano Sanchez A, Lluch Hernández A, Minambres R, Benitez J. BMC Cancer.2020 Nov 10;20(1):1079. doi: 10.1186/s12885-020-07584-9. PMID: 33167914

HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women. Oltra Sanchis S, Cejalvo Andujar J, Tormo Martin E, Albanell M, Ferrer A, Nacher M, Bermejo De Las Heras B, Hernando Meliá C, Chirivella González I, Alonso Yuste E, Burgues Gasion O, Peña Chilet M, Eroles Asensio P, Lluch Hernández A, Ribas Despuig G, Martinez Martinez M. Cancers. 2020 Feb 10;12(2):412. doi: 10.3390/cancers12020412. PMID: 32050699

KSHV G-protein coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase-2 expression mediates angiogenesis and tumorigenesis in Kaposi’s sarcoma. Medina M, D’Agostino A, Ma Q, Eroles P, Cavallin L, Chiozzini C, Sapochnik D, Cymeryng C, Hyjek E, Cesarman E, Naipauer J, Mesri E, Coso O. PLoS pathogens. 2020 Oct 15;16(10):e1009006. doi: 10.1371/journal.ppat.1009006. PMID: 33057440

MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma. Pattanayak C, Garrido Cano I, Adam Artigues A, Tormo Martin E, Pineda Merlo B, Cabello Navarro P, Alonso Yuste E, Bermejo De Las Heras B, Hernando Meliá C, Martinez Martinez M, Rovira A, Albanell J, Rojo F, Burgues Gasion O, Cejalvo Andujar J, Lluch Hernández A, Eroles Asensio P. Frontiers in Oncology. 2020 Sep 10;10:1661. doi: 10.3389/fonc.2020.01661. PMID: 33014831

miRNA expression Analysis: cell lines HCC1500 and HCC1937 as models for breast cancer in young women and the miR-23a as a poor prognostic biomarker. Oltra SS, Peña-Chilet M, Martinez MT, Tormo E, Cejalvo JM, Climent J, Eroles P, Lluch A, Ribas G. Breast Cancer. 2020 Dec 2;14:1178223420977845. doi: 10.1177/1178223420977845. PMID: 33311984

Mu Opioid Receptor 1 (MOR-1) Expression in Colorectal Cancer and Oncological Long-Term Outcomes: A Five-Year Retrospective Longitudinal Cohort Study. Diaz-Cambronero O, Mazzinari G, Giner F, Belltall A, Ruiz-Boluda L, Marques-Mari A, Sanchez-Guillen L, Eroles Asensio P, Cata J, Argente-Navarro M. Cancers. 2020 Jan 5;12(1):134. doi: 10.3390/cancers12010134. PMID: 31948099

The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.. Gonzalez-Alonso P, Zazo S, Martin-Aparicio E, Luque M, Chamizo C, Sanz-Alvarez M, Minguez P, Gomez-Lopez G, Cristobal I, Carames C, Garcia-Foncillas J, Eroles Asensio P, Lluch Hernández A, Arpi O, Rovira A, Albanell J, Piersma S, Jimenez C, Madoz-Gurpide J, Rojo F. Cancers. 2020 Apr 29;12(5):1108. doi: 10.3390/cancers12051108. PMID: 32365528

Projects
Reference: PI21/01351
Title: Predicción de enfermedad residual después de la terapia neoadyuvante en cáncer de mama HER2 positivo e identificación de estrategias para superar la resistencia
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Pilar Eroles Asensio
Duration: 2022 – 2024
Total budget: 123.420 €
Reference: PI18/01219
Title: Caracterización y repercusión terapéutica de la ecología de cáncer de mama HER2 positivo
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Pilar Eroles Asensio
Duration: 2019 – 2021
Total budget: 112.530 €
Reference: COST Action CA15204
Title: European Platform for Outcomes Research into Perioperative Interventions during Surgery for Cancer
Funding body: European Commission
Principal Investigator: Pilar Eroles Asensio
Duration: 2016 – 2020
Total budget:
+ Info
Title: Overcoming resistance to HER2 blockade in breast cancer: AXL as a promising druggable target and prognostic biomarker
Doctoral candidate: Adam Artigues, Anna
Director(s): Lluch Hernández, Ana; Eroles Asensio, Pilar
Date of the defense: 12/04/2022
University: Universitat de València

Title: Role of miR-99a-5p in breast cancer: translating molecular findings into clinical tool
Doctoral candidate: Garrido Cano, Iris
Director(s): Eroles Asensio, Pilar; Martínez Máñez, Ramón
Date of the defense: 17/12/2021
University: Universitat Politècnica de València

Title: Involvement of EZH2-MYC loop and SALL4 in epithelial-mesenchymal transition (EMT) and trastuzumab resistance process in HER2+ breast cancer
Doctoral candidate: Pattanayak Pattanayak, Chaudhuri Birlipta
Director(s): Eroles Asensio, Pilar; Cejalvo Andújar, Juan Miguel
Date of the defense: 26/02/2021
University: Universitat de València

Title: Epigenetic regulation of resistance to treatments in triple negative and HER2+ breast cancer: mirnas involved
Doctoral candidate: Cabello Navarro, Paula
Director(s): Erolés Asensio, Pilar; Lluch Hernández, Ana
Date of the defense: 28/09/2020
University: Universitat Politècnica de València